Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022
LAKE FOREST, Ill., March 02, 2022 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the…
News
CORRECTION – Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with…
Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
Dr. Paulson Will Lead Clinical Efforts Focused on Capricor’s Late-Stage Cell Therapy Program and its…
Shattuck Labs Announces Participation in Upcoming March Conferences
AUSTIN, TX and DURHAM, NC, March 02, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck)…
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2021 Financial Results and Host a Conference Call on Wednesday, March 9, 2022
WOBURN, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the…
Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and…
SCYNEXIS to Participate in Upcoming Scientific Conferences and Events
JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage…
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual…
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue…
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage…
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Supernus to Participate in Annual Cowen Health Care Conference
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc….
Alimera Sciences to Present at the Q1 Investor Summit Conference
ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage…
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage…
Molecular Templates Strengthens Board of Directors and Management Team
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General…